Marinus Pharmaceuticals, Inc. increased earnings guidance for full year 2024. For the year, company projected U.S. ZTALMY net product revenues to between $33 and $35 million from a range of $32 Million and $34 Million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.5 USD | +8.70% | +13.16% | -86.15% |
May. 17 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
May. 17 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.15% | 75.81M | |
+37.44% | 727B | |
-7.89% | 354B | |
+15.47% | 328B | |
-0.63% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+3.79% | 164B | |
-2.15% | 164B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024